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ABSTRACT 
 
This report presents a female diagnosed with a frontoparietal interhemispheric 
meningosarcoma who, parallel to the clinical worsening, revealed an increase in the 
genetic instability (in bleomycin cultures) and the complexity of the karyotypes, with 
the acquisition of a clonal deletion of 17p13 (the locus for the TP53 tumor suppressor 
gene). The genetic findings of this patient suggest that the increased genetic instability 
could contribute to tumor progression as well as to treatment resistance, possibly in the 
background of the clonal deletion of TP53.  
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Meningeal sarcomas are tumors arising from mesenchymal and nonmeningothelial cells 
which account for less than 3% of all pediatric central nervous system tumors. These 
tumors are slightly more frequent in the second decade of life, are highly aggressive, 
and rarely respond to conventional antitumoral treatment [1]. In the past, meningeal 
sarcomas were classified as a subgroup of aggressive meningeal tumors, although they 
are nowadays excluded from that group [2] on the basis that the cells of origin are 
different, which can account for their distinct histopathologic and cytogenetic features. 
 
Several reports have characterized the most frequent chromosomal aberrations that are 
present in meningiomas. These aberrations are generally related to the aggressiveness or 
progression of the tumors (anaplastic malignant meningiomas) and include monosomy 
or deletion of chromosome 22 (NF2 locus), complete or partial loss of chromosome 1, 
and alterations affecting 10q, 14q, and 9q [3-4]. In contrast, these particular alterations 
are not evident in the meningosarcomas, whose genetic alterations are heterogeneous 
and to date largely undefined. 
 
The patient reported herein was submitted to our laboratory for examination because she 
was included in an investigation protocol aimed at analyzing the genetic instability 
induced by antitumoral regimens in pediatric patients [5]. 
 
 
 
MATERIALS AND METHODS 
 
Informed consent was obtained from the affected female and her parents, and the ethical 
approval was granted by the Ethics Committee of the University Clinic, Pamplona, 
Spain. 
 
Chromosomal studies were performed on peripheral blood samples following standard 
procedures. A minimum of 50 well-spread metaphases, obtained from 72-hour 
phytohemagglutinin-stimulated cultures, were analyzed. Chromosomal abnormalities, 
identified by G-banding, were described according to the international system for 
human cytogenetic nomenclature [6]. 
 
Bleomycin cultures were established as previously described [5]. Breaks were scored in 
50 metaphases per sample, and the number of breaks per cell (b/c index) was averaged. 
Only chromatid breaks or exchanges were recorded; chromatid gaps or attenuated 
regions were disregarded. A b/c index above 0.8 was considered to indicate sensitivity 
to bleomycin-induced chromosome damage, and an index above 1.0 was considered to 
indicate hypersensitivity. 
 
 
 
CASE REPORT 
 
The patient was a 9-year-old female with antecedents of cephalgia and unspecified 
visual alterations for 2 months. The computed tomographic scan revealed a 
frontoparietal interhemispheric lesion which was compatible with a meningioma. 
Complete macroscopic resection was achieved, with an inconclusive pathologic 
diagnosis of meningeal tumor with moderate atypia and areas of cortical infiltration. 
Within 2 months, the patient relapsed, and the new tumor mass was incompletely 
resected because of cortical infiltration. Microscopic examination revealed a 
mesenchymal neoplasia suggestive of meningosarcoma. One month later, complete 
macroscopic resection of the infiltrating lesion of the medial line was again performed, 
tumoral areas were more differentiated, there were atypias and carcinomatosis. With the 
diagnosis of relapsed meningeal sarcoma, she was admitted to the Clínica Universitaria, 
Pamplona in September 1997. 
 
At admittance (Stage 1, S1 in Table 1), the cerebral magnetic resonance imaging 
revealed frontoparietal tumoral lesions, predominantly left-sided and in the 
interhemispheric furrow with distension of the ventricular system (Fig 1A). The 
cytologic study revealed atypical cells in the cerebrospinal fluid. Cytogenetic analysis 
indicated increased chromosomal instability (b/c index = 1.4) and the presence of an 
abnormal but nonclonal karyotype. The patient then began with chemotherapy (ICE 
protocol: ifosfamide, carboplatin, and etoposide) and cranial radiotherapy. 
 
In 4 months (S2, Table 1), after four chemotherapy cycles, there was improvement in 
the magnetic resonance imaging with persistence of the increased signal at the 
ependymal level (Fig 1B) and normalization of the cytology of the cerebrospinal fluid. 
Nevertheless, cytogenetic studies documented an increase in genetic instability (b/c 
index = 1.93) and in the number and complexity of the chromosomal aberrations in 
several nonclonal karyotypes (Table 1). 
 
After two further cycles of chemotherapy, worsening in clinical condition was evident, 
with carcinomatous dissemination, thickening of the leptomeninges and the ventricular 
system walls (Fig 1C), and cytologic alteration of the cerebrospinal fluid. By this stage 
(S3, Table 1), the genetic instability had increased to 2.83 and the karyotypes 
manifested multiple chromosomal aberrations including the acquisition of a clonal 
alteration: two metaphases revealed deletion at 17p13, the locus of the TP53 tumor 
suppressor gene. 
 
The patient’s clinical condition continued to worsen despite aggressive treatment with 
chemotherapy, spinal radiotherapy, and bone marrow transplantation. The patient died 2 
months later as a result of craniospinal carcinomatosis and lung metastases. 
 
 
 
DISCUSSION 
 
To date, neither the etiology nor the genetic pathways that lead to human 
meningosarcomas are clear; nevertheless, the finding of meningothelial elements within 
certain sarcomas has led some authors to hypothesize that the secondary sarcomatous 
changes in a preexisting meningioma might be considered as a meningosarcoma variant 
[2]. This difference is, in some instances, difficult to assess but still crucial given that 
the differences in both the histopathologic and genetic markers point to clinical entities 
which differ; specifically in terms of genomic instability which could play a role in the 
progression of some meningiomas [7]. 
The clinical case detailed herein was included in a protocol to evaluate the genetic 
instability induced by antitumoral regimens. Among other tumor types, 23 pediatric 
central nervous system tumors were analyzed [5]. We and others have demonstrated that 
these tumors do not manifest a significantly increased genetic instability at diagnosis. 
However, in the case of this female, both an increased sensitivity to bleomycin and an 
aberrant karyotype before the beginning of treatment were detected. In addition, the 
pathologic reports disclosed an evident deterioration between the first and second 
resection samples, with an increase in the number of mitoses and atypias and a clear 
evolution from a low-grade mesenchymal tumor to a malignant meningosarcoma. There 
is a lack of studies that evaluate the genomic instability in meningosarcomas, but there 
are several reports that relate this instability to the progression of meningiomas [7], 
precancerous lesions of the aerodigestive tract, or the development of relapses or second 
tumors of the upper aerodigestive tract. 
 
Another significant finding in this case is that despite the initial clinical and radiologic 
improvement, even with normalization of the cerebrospinal fluid, there was an 
outstanding increase both in chromosomal fragility in bleomycin tests and in peripheral 
blood karyotypes, with the development of a clonal deletion (in two metaphases) of 
17p13, the locus of the TP53 tumor suppressor gene. 
 
The TP53 gene is a tumor suppressor gene that is frequently altered in sporadic human 
tumors, including those of the central nervous system. The data on the involvement of 
this gene in the progression or carcinogenesis of human meningeal tumors are scarce 
and controversial [8-10]. There is some evidence to suggest that the traditional 
antineoplastic treatments, namely radiotherapy and chemotherapy, may act by p53-
mediated apoptosis and, therefore, those cells with an altered TP53 might manifest an 
increased resistance to treatment-induced apoptosis. In the case reported here, the clonal 
deletion of 17p13 was coincident with a rapid worsening in clinical condition, 
development of cerebrospinal carcinomatosis, and multiple lung metastases which 
manifested no response to the most aggressive treatments. 
 
Unfortunately, we lacked tumor tissue required for confirmation of the results obtained 
in peripheral blood lymphocytes given that, when the clonal deletion of TP53 
developed, there was an evident clinical deterioration, and therefore, surgery was not 
performed. However, in the reference literature, there are reports that conclude that 
peripheral blood cultures of patients with different types of cancer (lung, breast, 
melanoma, colon, renal cell) have chromosomal breaks that are also marker 
chromosomes for their respective tumors [11]. 
 
In conclusion, given the aggressiveness and the poor response of this tumor to 
conventional treatments, it would be interesting to include a larger number of 
meningosarcomas in genetic instability studies to evaluate the role of genetic instability 
in pathogenesis and progression and in order to facilitate the optimization of individual 
treatment protocols. 
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Table 1. Cytogenetic findings at the different moments of the follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Magnetic resonance imaging findings at different stages of the follow-up 
(spin-echo T1-weighted image [TR 550 ms, TE 14 ms], paramagnetic contrast 
enhanced). (A) Frontoparietal tumoral lesions, predominantly left-sided and in the 
interhemispheric fissura with distension of the ventricular system. (B) Improvement in 
the magnetic resonance imaging with persistence of the hypersignal at the ependymal 
level. (C) Carcinomatous dissemination, thickening of the leptomeninges and the 
ventricular system. 
 
 
 
 
 
 
